
Maravai LifeSciences Holdings, Inc.: stock overview
Price
$7.54
November 13, 2026Market cap $1.1B
What Ploutos Investor adds for Maravai LifeSciences
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Maravai LifeSciences had revenue of $213M over the last 12 months and a net loss of $66M. Revenue fell by 8.2% a year on average over the last 5 years. It has net debt of $103M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $1.1B
- 144M shares
- P/E
- –
- Revenue, 12 months
- $213M
- -8.2% a year over 5 years
- Net margin
- -30.8%
- 2025: -70.4%, above 18% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
-19.8% a year over 2 years
Fiscal years in figures
MRVI's revenue, profit, cash flow and dividend with each year-end price, from 2019 to 2022, 4 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $752M
- $1.1B
- Enterprise value
- $1.2B
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- 5.6
- P/B 3-year median: 2.2
- 5.6
- FCF yield 3-year median: -3.0%
- –
- Earnings yield 3-year median: -19.3%
- –
Profitability
- Gross margin
- 39.2%
- Operating margin
- -45.4%
- Net margin 3-year median: -55.9%
- -30.8%
- ROIC
- -17.4%
- ROIC, 5-year average
- 5.3%
- ROE
- -30.7%
Growth
- Revenue, yearly change
- -28.3%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- -8.2%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $73M
- Total debt
- $226M
- Of which operating leases
- $49M
- Net debt
- $103M
- Net debt / EBITDA
- –
- Interest cover
- -4.6x
- Current ratio
- 4.66
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +4.7%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).
Gross margin
18.3%
Above 17% of the 141 companies in its industry, and 19% of all.
Operating margin
-115.9%
Above 15% of the 285 companies in its industry, and 3% of all.
Net margin
-70.4%
Above 18% of the 302 companies in its industry, and 5% of all.
ROE
-61.6%
Above 12% of the 267 companies in its industry, and 6% of all.
ROA
-17.0%
Above 27% of the 313 companies in its industry, and 10% of all.
Revenue growth
-28.3%
Above 7% of the 292 companies in its industry, and 3% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- MARAVAI LIFESCIENCES HOLDINGS, INC.
- CIK
- 1823239
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 144M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with MRVI
- JNJJohnson & Johnson+0,00%Compare with MRVI
- ABBVAbbVie+0,00%Compare with MRVI
- UNHUnitedHealth+0,00%Compare with MRVI
- MRKMerck & Company+0,00%Compare with MRVI
- AMGNAmgen+0,00%Compare with MRVI
- TMOThermo Fisher Scientific+0,00%Compare with MRVI
- ABTAbbott Laboratories+0,00%Compare with MRVI
The full analysis
What do Maravai LifeSciences's filings show?
These are Maravai LifeSciences's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is MRVI's market cap?
Maravai LifeSciences Holdings, Inc.'s market cap is $1.1B, at a price of $7.54 on November 13, 2026 and 144M shares.
How much revenue does MRVI have?
Maravai LifeSciences had revenue of $213M over the last 12 months. Over the last 5 years it changed by -8.2% a year on average.
Does MRVI pay a dividend?
No. Maravai LifeSciences paid no regular dividend over the last 12 months.
Where do the figures come from?
From Maravai LifeSciences Holdings, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.